X0206 3 2013-08-21 0 0001311596 Regado Biosciences Inc RGDO 0001170144 QUAKER BIO VENTURES LP C/O CIRA CENTRE 2929 ARCH STREET PHILADELPHIA PA 19104 0 0 1 0 0001223034 QUAKER BIOVENTURES CAPITAL LP C/O CIRA CENTRE 2929 ARCH STREET PHILADELPHIA PA 19104 0 0 1 0 Common Stock, par value $0.001 per share 35928 D Series B Preferred Stock 2005-07-27 Common Stock, par value $0.001 per share 399201 D Series C Preferred Stock 2007-03-15 Common Stock, par value $0.001 per share 273468 D Series D Preferred Stock 2009-12-17 Common Stock, par value $0.001 per share 360529 D Series D Preferred Stock 2011-05-25 Common Stock, par value $0.001 per share 104723 D Series E Preferred Stock 2012-12-18 Common Stock, par value $0.001 per share 43171 D Series E Preferred Stock 2013-03-22 Common Stock, par value $0.001 per share 5191 D The reportable securities are directly held by Quaker BioVentures, L.P. (the "Reporting Person"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Reporting Person. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by the Reporting Person. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by the Reporting Person are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff, a member of the board of the directors of the Issuer. The shares of Series B Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series C Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series D Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series E Preferred Stock have no expiration date and shall automatically convert upon the consummation of the Issuer's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. Quaker BioVentures, L.P. By: /s/ P. Sherrill Neff, the member of Quaker BioVentures Capital, LLC, the general partner of Quaker BioVentures Capital, L.P. 2013-08-21 Quaker BioVentures Capital, L.P. By: /s/ P. Sherrill Neff, member of Quaker BioVentures Capital, LLC, the general partner of Quaker BioVentures Capital, L.P., the general partner of Quaker BioVentures, L.P. 2013-08-21